Key result
Statin therapy linked to ~86% fewer cardiac events and attenuated pro-inflammatory cytokines in dyslipidemic CHF.
Why the study?
The effects of statin therapy on monocyte pro-inflammatory cytokine production, cardiac function, and long-term prognosis in CHF patients with dyslipidemia remain unclear.
Does statin therapy reduce monocyte pro-inflammatory cytokines, improve cardiac function, and prevent cardiac events in chronic heart failure patients with dyslipidemia?
Cohort (n=146)
Yes
Does statin therapy reduce monocyte pro-inflammatory cytokines, improve cardiac function, and prevent cardiac events in chronic heart failure patients with dyslipidemia?
Answers are grounded in this paper and cite their sources.
In patients with chronic heart failure and dyslipidemia, statin therapy is associated with reduced pro-inflammatory cytokine production, improved left ventricular function, and a lower risk of long-term cardiac events.
BACKGROUND: The effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function and the long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear. METHODS AND RESULTS: A total of 146 CHF patients with a mean left ventricular ejection fraction (LVEF) of 26.9 ± 6.6% were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=63) and a no statin group (n=83). Only patients with dyslipidemia were treated with statins. Peripheral blood mononuclear cells (PBMCs) were isolated, and the production of monocyte tumor necrosis factor (TNF)-α and interleukin (IL)-6 were measured at baseline and after 6 months of treatment, and the data expressed as mean ± SD (pg·ml(-1)·10(-6) PBMCs). The LVEF in the statin group improved, and the monocyte TNF-α and IL-6 production decreased (respectively, P<0.001), but the LVEF and cytokine production remained unchanged in the no statin group. Multivariate Cox hazard analysis showed that statin therapy (hazard ratio, 0.14; 95% confidence interval: 0.02-0.97, P=0.046) was an independent predictor of cardiac events. CONCLUSIONS: Statin therapy attenuates the production of monocyte pro-inflammatory cytokines, and ameliorates the cardiac function and may improve long-term prognosis in CHF patients with dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Nakagomi et al. (2012) conducted a cohort in Chronic heart failure with dyslipidemia (n=146). Statin therapy vs. No statin therapy was evaluated on Cardiac events (cardiac death and readmission due to worsening of CHF) (HR 0.14, 95% CI 0.02-0.97, p=0.046). Statin therapy reduced the risk of cardiac events and attenuated the production of monocyte pro-inflammatory cytokines in patients with chronic heart failure and dyslipidemia.
Synapse has enriched 10 related papers. Consider them for comparative context: